Sequential use of PI3K/AKT/mTOR pathway inhibitors alpelisib and everolimus in patients with hormone receptor-positive metastatic breast cancer.
Saved in:
| Title: | Sequential use of PI3K/AKT/mTOR pathway inhibitors alpelisib and everolimus in patients with hormone receptor-positive metastatic breast cancer. |
|---|---|
| Authors: | Shen S; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Teysir J; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Safonov A; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Bromberg M; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Chen Y; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Ahmed M; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Razavi P; Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Medical Center, New York, NY, USA., Jhaveri K; Memorial Sloan Kettering Cancer Center, New York, NY, USA. jhaverik@mskcc.org.; Weill Cornell Medical Center, New York, NY, USA. jhaverik@mskcc.org. |
| Source: | Breast cancer research : BCR [Breast Cancer Res] 2026 Jan 31; Vol. 28 (1). Date of Electronic Publication: 2026 Jan 31. |
| Publication Type: | Journal Article; Observational Study |
| Journal Info: | Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 100927353 Publication Model: Electronic Cited Medium: Internet ISSN: 1465-542X (Electronic) Linking ISSN: 14655411 NLM ISO Abbreviation: Breast Cancer Res Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1465-542X |
|---|---|
| DOI: | 10.1186/s13058-025-02152-0 |
